Introduction {#s1}
============

*Escherichia coli* is a gram-negative bacterium, which can cause intestinal (diarrhea) or extraintestinal (urinary tract infection, septicaemia, pneumonia, and meningitis) diseases in humans and animals (Cabal et al., [@B7]). Current antibiotic treatments used to treat *E. coli often* result in a spread of multidrug resistance (MDR) of *E. coli* (Lepape and Monnet, [@B28]). For example, *E. coli* strains produce Extended-Spectrum Beta Lactamase and metallo-β-lactamas, enzymes which make *E. coli* become resistant to several antibiotic drugs (Peña et al., [@B33]; Birgy et al., [@B4]). Currently, carbapenems appear to be the last available treatment for the severe infections caused by MDR *E. coli*. The recent finding of carbapenemase which hydrolyzes carbapenem may soon lead to cases with no therapeutic issue (Birgy et al., [@B4]). The emergence of carbapenemase and the lack of efficient antibiotics are alarming, therefore, the well-tolerated, highly effective therapeutic alternatives are urgently needed (Birgy et al., [@B4]; Castanheira et al., [@B10]). This has encouraged researchers into returning to use bacteriophages (phages) as a supplement or substitute of antibiotics to treat infection caused by bacterial (Bolocan et al., [@B5]).

Although phages have been discovered over a century ago, phages continue to have a major impact on modern biological sciences, especially with the growth of interests in the microbiome (Haq et al., [@B20]; Laanto et al., [@B27]) and treating multidrug-resistant bacteria (Kutateladze and Adamia, [@B26]; Bolocan et al., [@B5]). Many reports described that various pathogenic *E. coli* have been killed by lysis phages (Bourdin et al., [@B6]). Therapeutic bacteriophages that efficiently lyse the *E. coli* O104:H4 outbreak strain could be selected easily from a phage bank or isolated from the environment (Merabishvili et al., [@B30]). Phage EC200PP was able to treat sepsis and meningitis infections induced by drug-resistant *E. coli* S242 (Pouillot et al., [@B35]). Fitzgerald-Hughes\'s study proved that Extended-Spectrum Beta Lactamase producing *E. coli* strains can be killed by commercially available and laboratory-isolated bacteriophages (Fitzgerald-Hughes et al., [@B18]). Dufour et al. determined that bacteriophage LM33-P1 can infect β-lactams and fluoroquinolones resistant *E. coli* strains efficiently both *in vitro* and *in vivo* (Dufour et al., [@B16]). The study on the efficient treatment of *E. coli*-induced pneumonia with two bacteriophages (536 P1 and 536 P7) showed that a combination of antibiotic treatment and phage therapy resulted in a 100% survival rate in VAP-infected mice (Dufour et al., [@B17]). Therefore, bacteriophages can be used as a supplement for antibiotics to treat the infection caused by bacteria.

Phages are the most abundant biological entities present on earth, providing an unlimited resource for possible phage applications (Srinivasiah et al., [@B41]). Phages flourish in oceans, soil, wastewater treatment plants, hot-water springs, and animal gut (Srinivasiah et al., [@B41]; Williamson et al., [@B44]). *E. coli* phages are commonly isolated from sewage, hospital waste water, polluted rivers, and fecal samples of humans or animals (Jamalludeen et al., [@B25]; Dalmasso et al., [@B14]; Snyder et al., [@B40]; Amarillas et al., [@B2]). Selection of wide spectrum phages or phages cocktail components for therapeutic preparation are key procedures to overcome the shortage of phage therapy, such as narrow host range of phages and emergence of bacterial resistance to phages (Regeimbal et al., [@B36]). Constructing the "right" cocktail is essential for achieving the maximum effectiveness of phage therapy (Bourdin et al., [@B6]; Schooley et al., [@B37]). It is also essential to have a set of well-characterized phages available for constructing the "right" cocktail to infect the broad range of bacterial pathogens (Sybesma et al., [@B43]). Therefore, isolating new phages and unraveling their genome sequence seems to be urgently needed to accumulate sufficient phage stocks for phage therapy.

In the present study, we isolated a lytic phage named vB_EcoS-B2 from waste water. Transmission electron microscopy of vB_EcoS-B2 morphology revealed that it belongs to the *Siphoviridae* family. vB_EcoS-B2 significantly reduced the growth of *E. coli* under laboratory conditions. Prior to its application in phage therapy, we determined the genomic sequence and particle proteins of phage vB_EcoS-B2. Our results confirmed that vB_EcoS-B2 does not include virulent genes, islands of pathogenicity, or genes through lysogeny or transduction, which is a good candidate for phage therapy.

Materials and methods {#s2}
=====================

Bacterial strains and culture conditions
----------------------------------------

The bacterial strains used in this study were listed in Table [1](#T1){ref-type="table"}. *E. coli* strains BL21 (DE3), DH5α, JM110, TOP10, BW25113, S17-1 were stocks in our lab. Thirty-five clinical isolates of *E. coli* were isolated from clinical samples of patients in the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. All clinical strains which were used for phage host range determination have antibiotic resistance. Twenty-one of them are Extended-Spectrum Beta Lactamase producing stains. Five of them are metallo-β-lactamas (New Delhi metallo-β-lactamase-5) producing stains. All strains were grown in Luria--Bertani (LB) medium at 37°C.

###### 

Host range spectrum of thebacteriophage vB_EcoS-B2.

  ***E. coli* strain**    **Source**          **Subtype**   **Resistance**                                                                                                                                                                                                                                                               **Lysis or not**
  ----------------------- ------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  *E. coli* K-12 MG1655                                                                                                                                                                                                                                                                                                                  Clear plaque
  *E. coli* TOP10                                                                                                                                                                                                                                                                                                                        Clear plaque
  *E. coli* S17-1                                                                                                                                                                                                                                                                                                                        Clear plaque
  *E. coli* DH5α                                                                                                                                                                                                                                                                                                                         Clear plaque
  *E. coli* BW25113                                                                                                                                                                                                                                                                                                                      Clear plaque
  *E. coli* BL21(DE3)                                                                                                                                                                                                                                                                                                                    Clear plaque
  *E. coli* JM110                                                                                                                                                                                                                                                                                                                        N
  25922                   ATCC 25922          Non-ESBL                                                                                                                                                                                                                                                                                   N
  35218                   ATCC 35218          ESBL                                                                                                                                                                                                                                                                                       Turbid plaque
  389 A6                  Urine               ESBL          Aztreonam, cefazolin, ceftazidime, cefatriaxone, sulfamethoxazole, and trimethoprim                                                                                                                                                                                          Turbid plaque
  389 A9                  pus and secretion   ESBL          Aztreonam, cefazolin, ceftazidime, sulfamethoxazole, and trimethoprim                                                                                                                                                                                                        N
  389 D9                  Urine               Non-ESBL      Sulfamethoxazole and trimethoprim                                                                                                                                                                                                                                            N
  389 E6                  Urine               Non-ESBL      Levofloxacin                                                                                                                                                                                                                                                                 N
  389 G4                  Urine               Non-ESBL      Amikacin, Ampicillin sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, gentamycin, Levofloxacin,                                                                                                                                                N
  389 G6                  Urine               Non-ESBL      Levofloxacin                                                                                                                                                                                                                                                                 N
  389 G7                  Urine               ESBL          Amikacin, Ampicillin sulbactam, aztreonam, cefazolin, cefotaxime, Levofloxacin                                                                                                                                                                                               N
  389 J4                  Sputum              ESBL          Aztreonam, cefazolin, cefepime, ceftazidime, cefatriaxone,                                                                                                                                                                                                                   N
  390 A7                  Sputum              Non-ESBL      Sulfamethoxazole and trimethoprim                                                                                                                                                                                                                                            N
  390 B6                  Urine               Non-ESBL      Sulfamethoxazole and trimethoprim                                                                                                                                                                                                                                            N
  390 G7                  Urine               Non-ESBL      Ampicillin sulbactam, cefazolin, gentamycin, Levofloxacin, sulfamethoxazole, and trimethoprim                                                                                                                                                                                Clear plaque
  390 H2                  Urine               Non-ESBL      Ampicillin sulbactam, cefazolin, gentamycin, Levofloxacin, sulfamethoxazole, and trimethoprim                                                                                                                                                                                N
  390 J2                  Urine               Non-ESBL      Levofloxacin, minocycline, sulfamethoxazole, and trimethoprim                                                                                                                                                                                                                N
  391 D3                  Urine               Non-ESBL      Cefazolin, gentamycin, sulfamethoxazole, and trimethoprim                                                                                                                                                                                                                    N
  391 G4                  Blood               ESBL          Aztreonam, cefazolin, cefepime, ceftazidime, cefatriaxone,                                                                                                                                                                                                                   N
  393 B7                  Urine               ESBL          Amikacin, amoxicillin and clavulanate, Ampicillin sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, gentamycin, Levofloxacin, minocycline, sulfamethoxazole, and trimethoprim                                                                   N
  393 C1                  Ascites             ESBL          Ampicillin sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, ceftazidime, gentamycin, sulfamethoxazole and trimethoprim                                                                                                                                                 Clear plaque
  393 C8                  Urine               ESBL          Cefazolin, cefepime, cefotaxime, Levofloxacin, sulfamethoxazole, and trimethoprim                                                                                                                                                                                            N
  393 D3                  Urine               ESBL          Cefazolin, cefepime, cefotaxime, ceftazidime, Levofloxacin,                                                                                                                                                                                                                  N
  394 F7                  Urine               ESBL          Amoxicillin and clavulanate, aztreonam, cefazolin, cefotaxime, cefoxitin, ceftazidime                                                                                                                                                                                        N
  394 G1                  Urine               ESBL          Amoxicillin and clavulanate, cefazolin, cefoxitin, imipenem, sulfamethoxazole, and trimethoprim                                                                                                                                                                              N
  394 H7                  Urine               ESBL          Aztreonam, cefepime, cefotaxime, ceftazidime, Levofloxacin                                                                                                                                                                                                                   Clear plaque
  395 B5                  Urine               ESBL          Ampicillin sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, gentamycin, Levofloxacin, sulfamethoxazole, and trimethoprim                                                                                                                                               N
  395 G6                  Urine               ESBL          Aztreonam, cefazolin, cefepime, cefotaxime, ceftazidime, gentamycin                                                                                                                                                                                                          N
  395 J2                  Sputum              ESBL          Ampicillin, gentamycin, Levofloxacin, minocycline                                                                                                                                                                                                                            N
  396 F3                  Sputum              ESBL          Amikacin, ampicillin, gentamycin, Levofloxacin, minocycline                                                                                                                                                                                                                  Clear plaque
  396 J1                  Urine               ESBL          Cefazolin, cefepime, cefotaxime, imipenem, Levofloxacin,                                                                                                                                                                                                                     N
  396 J5                  Urine               ESBL          Aztreonam, cefazolin, cefepime, cefotaxime, imipenem, Levofloxacin                                                                                                                                                                                                           N
  397 C8                  Sputum              ESBL          Aztreonam, cefazolin, cefepime, ceftazidime, cefatriaxone                                                                                                                                                                                                                    N
  397 D3                  Urine               ESBL          Ampicillin sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, gentamycin, Levofloxacin, sulfamethoxazole, and trimethoprim                                                                                                                                    N
  37                      n.d                 NDM-5         Ampicillin/Sulbactam, aztreonam, imipenem, Levofloxacin, piperacillin, Cefuroxime sodium, cefuroxime axetil, sulfamethoxazole, and trimethoprim, ceftazidime, Tazobactam, Meropenem, cefotetan, cefatriaxone, cefazolin, Cefepime plaster                                    N
  40                      n.d                 NDM-5         Ampicillin/Sulbactam, amikacin, aztreonam, gentamycin, imipenem, Levofloxacin, piperacillin, Cefuroxime sodium, cefuroxime axetil, sulfamethoxazole and trimethoprim, ceftazidime, Tazobactam, tobramycin, Meropenem, cefotetan, cefatriaxone, cefazolin, Cefepime plaster   N
  64                      n.d                 NDM-5         Ampicillin/Sulbactam, gentamycin, imipenem, Levofloxacin, piperacillin, Cefuroxime sodium, cefuroxime axetil, sulfamethoxazole and trimethoprim, ceftazidime, Tazobactam, tobramycin, Meropenem, cefotetan, cefatriaxone, cefazolin, Cefepime plaster                        N
  69                      n.d                 NDM-5         Ampicillin/Sulbactam, amikacin, aztreonam, gentamycin, imipenem, Levofloxacin, piperacillin, Cefuroxime sodium, cefuroxime axetil, sulfamethoxazole and trimethoprim, ceftazidime, Tazobactam, tobramycin, Meropenem, cefotetan, cefatriaxone, cefazolin, Cefepime plaster   N
  92                      n.d                 NDM-5         Ampicillin/Sulbactam, gentamycin, imipenem, Levofloxacin, piperacillin, Cefuroxime sodium, cefuroxime axetil, sulfamethoxazole and trimethoprim, ceftazidime, Tazobactam, tobramycin, Meropenem, cefotetan, cefatriaxone, cefazolin, Cefepime plaster                        Turbid plaque

Positive results are indicated by "Clear plaque" or "Turbid plaque," and negative results are indicated by "N"; n.d., no data available; In the column "subtype," "ESBL" represent "Extended-Spectrum Beta Lactamase," "NDM-5" represent "New Delhi metallo-β-lactamase-5."

Isolation and propagation of bacteriophages
-------------------------------------------

*E. coli* MG1655 was used for isolating and enriching virulent bacteriophage from waste water in Nanjing. Sewage sample was filtered using 0.45 μm pore-size filters (Millipore, USA) to remove bacteria. Filtrates were added to *E. coli* MG1655 culture in early-log-phase at 37°C for 24 h with constant shaking to enrich the phages. Then the culture was centrifuged at 12,000 g for 10 min at 4°C to remove *E. coli* cells. The enriched phage suspension was tested for plaque formation with *E. coli* MG1655 using the double-layer agar plate method. Plaques formed on the plates after 12 h of incubation at 37°C. Single plaque was picked to start the second (and subsequent) round of amplification. The infection cycle was repeated until the plaques were homogeneous. The phages were then amplified and stored at 4°C.

Purification of phages
----------------------

Purification of vB_EcoS-B2 was carried out as described previously with slight modifications (Heo et al., [@B23]). Briefly, *E. coli* MG1655 culture at the early-log-phase (OD600 = 0.4) was infected by phage vB_EcoS-B2 at 37°C for 3 h with shaking. Cell debris was removed by centrifugation (14,000 g, 10 min, 4°C). The supernatant was passed through 0.45-μm-pore-size filters, yielding a crude extract of phage. Then the phage crude extract was concentrated by ultracentrifugation (100,000 g, 2h, 4°C), and the pellet containing phages was suspended in SM buffer (5.8 g/L NaCl, 2 g/L MgSO~4~·7H~2~O, 50 ml/L 1M pH7.5 Tris-HCl). The concentrated suspension was further purified by cesium chloride gradient centrifugation (90,000 g, 20 h, 4°C). The phage zone was collected (about 1 mL) and diluted into 10 ml SM buffer, followed by participation at 200,000 g for 3 h to remove CsCl. Finally, the pellet was resuspended in SM buffer to yield the highly purified vB_EcoS-B2 particles.

Electron microscopy
-------------------

The purified phage particles of vB_EcoS-B2 were fixed on a copper grid with a carbon-coated film and negatively stained with 2% (w/v) phosphotungstic acid. The micrographs were taken under FEI Tecnai G2 Spirit Bio TWIN transmission electron microscope at 80 kV.

Temperature stability
---------------------

The stability of bacteriophage under different temperature conditions was determined by constant temperature water bath method, a 1.5 mL tube containing 200 μL (approximately 10^10^ pfu/mL) equal volumes of phage were incubated under different temperature (4, 25,37, 45, 50, 55, 60, and 65°C). The phage titer was determined at intervals of 30 min from 0 to180 min, then at 6 and 24 h by the double-layer method. Three independent experiments were done and the value is represented by means.

Host range analysis
-------------------

Ability of vB_EcoS-B2 to infect *E. coli* strains was tested. A total of 10^9^ cells were mixed with melted agar, and this mixture was poured on solid agar to make double-layer agar plates. After solidification, 10 μL of phage suspensions (approximately 10^10^ pfu/mL) of bacteriophage stock suspensions was spotted on plates carrying each bacterial strain. After adsorption of the spots, the plates were inverted and incubated for 24 h at 37°C before the degree of lysis was scored (Postic and Finland, [@B34]). All experiments were conducted according to the standard institutional guidelines of Nanjing Medical University (Nanjing, China). The study was approved by the research and ethics committee of the First Affiliated Hospital of Nanjing Medical University.

One-step growth curve
---------------------

One-step growth experiment was carried out as described previously with little modification (Yang et al., [@B45]). In brief, *E. coli* MG1655 was grown in LB medium until the early-log-phase (1 × 10^8^ CFU/mL). Phage vB_EcoS-B2 was added to *E. coli* MG1655 culture at a multiplicity of infection (MOI) of 10 separately, and allowed to absorb for 10 min at 37°C. Then the mixture was centrifuged at 14, 000 g for 1 min to remove un-adsorbed phages. After washing twice with fresh LB medium, the pellet of infected cells was resuspended in 50 mL of LB medium and the culture was continuously incubated at 37°C. Using double-layer agar plate method, we determined the free bacteriophage count at each time point. The latency period and burst period were obtained directly from these one-step growth curves. The burst size of vB_EcoS-B2 was calculated by dividing the phage titers at plateau phase by the initial number of infective bacterial cells.

Bacterial challenge assay
-------------------------

For the bacterial challenge assay, 50 mL fresh LB broth was inoculated with an overnight culture of *E. coli* MG1655 (1% inoculum), followed by incubation at 37°C at 220 rpm until the OD600 was about 0.3. vB_EcoS-B2 stock solutions were then added (MOI = 10) to these cultures. Bacterial growth was monitored by measuring the OD600 at various time points. As a negative control, bacterial cultures were inoculated with SM buffer instead of vB_EcoS-B2. OD600 was recorded at 15 min intervals, over a period of 300 min.

Extraction and sequencing of the vB_EcoS-B2 genome
--------------------------------------------------

The purified phage sample was treated with DNase I (New England Biolabs) and RNase A (Tiangen Biotech) for 2 h at 37°C to digest the exogenous DNA and RNA. The preparation was then treated with proteinase K (Tiangen Biotech) for 15 min at 55°C. The phage genome DNA was further prepared with a TIANamp Bacteria DNA Kit (Tiangen Biotech). DNA concentration was determined using a spectrophotometer (Nanodrop Technologies, USA). The vB_EcoS-B2 genomic DNA was sequenced using an Illumina HiSeq 2500 sequencer and reads were assembled into a whole genome using SOAPdenovov2.04 software and GapCloserv1.12.

Annotation and comparison
-------------------------

Putative open reading frames (ORFs) were predicted using artemis software (<http://www.sanger.ac.uk/science/tools/artemis>) and Glimmer 3 (Aggarwal and Ramaswamy, [@B1]), with a threshold of 30 amino acids (aa) as a minimum for the length of protein. Function annotation was performed using the BLAST tools at NCBI (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) against the non-redundant protein sequences database. Transfer RNAs (tRNAs) were identified using tRNAscan-SE (v1.23, <http://lowelab.ucsc.edu/tRNAscan-SE>) and ribosome RNAs (rRNAs) were determined using RNAmmer (v1.2, <http://www.cbs.dtu.dk/services/RNAmmer/>). DNAman was used to calculate molecular masses and isoelectric points for predicted phage proteins. The whole viral nucleotide sequence similarities between phages were determined by megablast analysis at NCBI. The global alignment of putative amino acid sequences was carried out by EMBOSS Needle tool at EMBL-EBI (European Molecular Biology Laboratory-European Bioinformatics Institute). Comparison of ORFs from relative phages was performed using EasyFig (<http://mjsull.github.io/Easyfig/files.html>) (Sullivan et al., [@B42]). Phylogenetic analyses between the genomes of related phages were performed with MEGA using the Neighbor-Joining algorithm.

Structural protein analysis of vB_EcoS-B2
-----------------------------------------

The highly purified phage sample was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 12% acrylamide concentration. Gels were stained with silver as described by Shevchenko et al. ([@B39]). For protein identification by liquid chromatography electrospray ionization with tandem mass spectrometry (LC-ESI MS/MS), the phage particles were digested with trypsin, and the tryptic peptides were analyzed by Q Exactive mass spectrometer (Thermo Scientific, USA). The corresponding ORFs were searched using MASCOT engine (Matrix Science, London, UK; version 2.2) against the protein sequence library of vB_EcoS-B2.

Nucleotide sequence accession number
------------------------------------

The genome sequence of vB_EcoS-B2 was deposited in GenBank under the accession number [MG581355](MG581355).

Results and discussion {#s3}
======================

Phage morphology
----------------

A new *E. coli* phage vB_EcoS-B2 was isolated from wastewater in Nanjing. The phage formed clear round plaque (about 1--3 mm-diameter) with *E. coli* strain MG1655 after overnight culture at 37°C (Figure [1A](#F1){ref-type="fig"}). The purified phage particles of vB_EcoS-B2 were examined under the Transmission Electron Microscope. vB_EcoS-B2 has an icosahedral symmetry head and a long tail without a contractile sheath, indicating that it belongs to the family of *Siphoviridae*. The isometric head of vB_EcoS-B2 had a mean diameter of 48 nm, and the long non-contractile tail was about 143 ± 6 nm (Figure [1B](#F1){ref-type="fig"}). vB_EcoS-B2 is closely resembled to the morphology of *Enterobacteria* phage SSL-2009a (an icosahedral head 62 nm in diameter and a long, flexible tail 138 nm in length) and *Shigella* phage EP23 (head diameter 59 ± 3 nm; non-contractile, filamentous tails 142 ± 32 nm in length) (Li et al., [@B29]; Chang and Kim, [@B12]).

![Isolation, morphology, and biological properties of phage vB_EcoS-B2. **(A)** Plaque morphology of phage vB_EcoS-B2. **(B)** Transmission electron micrographs of *E. coli* phage vB_EcoS-B2. Bar indicates 50 nm. **(C)** One-step growth curve of vB_EcoS-B2 on *E. coli* strain MG1655 at 37°C. **(D)** Thermo stability of vB_EcoS-B2: the phages were incubated at different temperatures for 24 h. Each value is the average from three different cultures ± standard deviation in **(C,D)**.](fmicb-09-00793-g0001){#F1}

Phage population dynamics
-------------------------

One-step growth experiments were performed to assess the population kinetics of vB_EcoS-B2, in the presence of *E. coli* strain MG1655 (Figure [1C](#F1){ref-type="fig"}). vB_EcoS-B2 had latent period about 20 min. All phages had been released by 30 min after infection (Figure [1C](#F1){ref-type="fig"}), and had a burst size of 224.1 ± 10.7 phage particles. Latent time of vB_EcoS-B2 was shorter than that of phage EP23 which had a latent period of 45 min (Chang and Kim, [@B12]). Latent and burst periods of vB_EcoS-B2 were very similar to that of phage SSL-2009a which have latent and burst periods 10--15 and 30--40 min (Li et al., [@B29]), respectively. Even though the burst size of vB_EcoS-B2 is less than that of SSL-2009a (about 375 PFU per infected cell) (Li et al., [@B29]), it is still a large burst size. As an antibacterial agent, a phage with a large burst size may indicate an easy selective advantage since phages with large burst sizes can increase the initial dose of phages several hundred-folds in short periods of time (Nilsson, [@B31]). The phages to be used in phage therapy must be strictly virulent and should be reproduced effectively and rapidly (Nilsson, [@B31]). Therefore, the large burst size and short latent time of vB_EcoS-B2 make it a good candidate for being used as the biocontrol agent against bacterial pathogens.

Thermal stability
-----------------

The thermal stability test was determined at different temperatures (4, 25, 37, 45, 50, 55, 60, and 65°C) whithin 24 h (Figure [1D](#F1){ref-type="fig"}). Results showed that the biological activity of phage vB_EcoS-B2 did not show any difference within the temperature ranging from 4 to 50°C, but decreased sharply when the temperature increasing above 55°C. Even though vB_EcoS-B2 does not like SSL-2009a which keeps activity more than 45 min over 63°C (Li et al., [@B29]), vB_EcoS-B2 is stable at relatively low temperature for longer time (Supplementary Figures [1](#SM1){ref-type="supplementary-material"}, [2](#SM1){ref-type="supplementary-material"}). The phage is stable over a range of temperatures (4--50°C) for 24 h, suggesting that it has a good thermal stability and therefore easy to be preserved.

Host range and effect of phages on *E. coli* growing culture
------------------------------------------------------------

The ability of newly isolated phage to lyse *E. coli* strains was assayed by the spot test. vB_EcoS-B2 can infect some of the well-known *E. coli* strains and several clinical MRD *E. coli* stains (Table [1](#T1){ref-type="table"}). vB_EcoS-B2 is similar to SSL-2009a that is able to infect some engineered *E. coli* strains (Table [1](#T1){ref-type="table"}). vB_EcoS-B2 can also infect the *E. coli* strain ATCC 35218, which could not be infected by SSL-2009a (Li et al., [@B29]). JL1 is a phage which can infect *E. coli* O157:H7 (Pan et al., [@B32]). EP23 can infect the three *E. coli* strains and two *S. sonnei* strains (Chang and Kim, [@B12]). The observations suggested that these very similar phages have different host range. Phage vB_EcoS-B2 only targeted seven MDR *E. coli* strains out of the 35 clinical isolates (Table [1](#T1){ref-type="table"}). Therefore, Phage vB_EcoS-B2 has a relative narrow host spectrum. To overcome the narrow host range of phages, it is generally accepted that cocktails of multiple phages can be used to kill the great diversity of *E. coli* strains (Schmerer et al., [@B38]).

The effect of vB_EcoS-B2 alone on the growth of strain MG1655 was tested at MOI = 10 after 300 min of the phage added into the strain. vB_EcoS-B2 can efficiently reduce the growth of *E. coli* MG1655 after 30 min of infection (Figure [2](#F2){ref-type="fig"}, Supplementary Figure [3](#SM1){ref-type="supplementary-material"}). Even though its host-range is relatively narrow, vB_EcoS-B2 has the possibility to be used as biocontrol agents against *E. coli* since it had strong lytic ability to *E. coli*. Therefore, it is essential to analyze complete sequence of vB_EcoS-B2 to ensure that the genome of vB_EcoS-B2 did not encode any genes associated with toxins, virulence factors, or lysogenic proteins.

![Bacterial challenge assay with phage vB_EcoS-B2 to *E. coli* MG1655. vB_EcoS-B2 was added at an MOI of 10 to the bacterial culture after 1.5 h incubation (OD600 = 0.25) (close circles). OD600 was recorded at 15 min intervals, over a period of 300 min. A bacterial culture inoculated with SM buffer instead of vB_EcoS-B2 was used as the negative control (open circles). Each value is the average from three different cultures.](fmicb-09-00793-g0002){#F2}

Basic characteristics of vB_EcoS-B2 genome
------------------------------------------

The complete genome of vB_EcoS-B2 is composed of a circular double stranded DNA of 44,283 bp in length, with 54.77% GC content which was slightly higher than those of *E. coli* (50.6%). Sixty-five putative open reading frames (ORFs) were predicted in the complete genome of vB_EcoS-B2. The annotation of the properties of phage vB_EcoS-B2 genome, such as positions, directions, and putative functions of each gene were summarized in Table [2](#T2){ref-type="table"}. Twenty-three ORFs were in the direct strand of the phage genome and 42 of them were in complementary strand (Figure [3](#F3){ref-type="fig"}). Only 25 ORFs (38.5%) were predicted and determined to be putative functional (different colors), whereas 40 ORFs were assigned to hypothetical proteins (black color) (Figure [3](#F3){ref-type="fig"}). The 25 predicted functional proteins were categorized into five functional groups: DNA replication/modification (DNA polymerase I, DNA helicase, putative DNA cytosine methyltransferase C5, putative HNH endonuclease, DNA methyltransferase, DNA recombination nuclease inhibitor gamma), host lysis (lysozyme, putative holin-like class I protein, and putative holin-like class II protein), packaging (terminase large subunit, putative terminase small subunit), structural proteins (putative tail tip protein, putative tail fiber protein, putative tail assembly protein I, tail assembly protein, putative minor tail protein L, putative minor tail protein, putative tail length tape-measure protein 1, putative major tail protein, putative tail protein, putative structural protein, major head protein, head morphogenesis protein, and phage structural protein), and additional functions (putative phosphoesterase) (Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}). In addition, in vB_EcoS-B2 genome no statistically significant BLASTP similarity was identified in genes encoding integrase, recombinase, repressor, and excisionase (markers of temperate bacteriophages) (Carrias et al., [@B8]). Consequently, the vB_EcoS-B2 phage should be considered as a virulent bacteriophage. Genome analysis also suggests that the phage vB_EcoS-B2 does not encode genes associated with toxins or other virulence factors. Virulent characteristics and no possible pathogen factors make it feasible to be a potential candidate for therapeutic application.

###### 

Predicted ORFs and genes encoded by the vB_EcoS-B2 genome.

  **ORFs**   **Start**   **Stop**   **Directions**   **No. of residues**   **MW(da)**   **pI**   **Predicted molecular function**
  ---------- ----------- ---------- ---------------- --------------------- ------------ -------- ---------------------------------------------
  ORF1       1           2,292      \+               763                   86167.7      8.56     DNA polymerase I
  ORF2       2,292       2,570      \+               92                    10147.2      10.39    Hypothetical protein
  ORF3       2,611       2,784      \+               57                    6825.7       10.35    Hypothetical protein
  ORF4       2,822       3,046      \+               74                    8761.5       9.94     Hypothetical protein
  ORF5       3,051       4,475      \+               474                   53461.8      9.55     DNA helicase
  ORF6       4,472       5,167      \+               231                   26496.7      8.27     Putative DNA cytosine methyltransferase C5
  ORF7       5,164       5,487      \+               107                   11695        9.14     Putative HNH endonuclease
  ORF8       5,569       6,033      \+               154                   17882.3      8.19     Hypothetical protein
  ORF9       6,020       6,505      \+               161                   18708.4      9.72     DNA methyltransferase
  ORF10      6,486       6,710      \+               74                    8686.6       8.9      Hypothetical protein
  ORF11      6,707       7,177      \+               156                   17872.8      6.25     Hypothetical protein
  ORF12      7,242       7,796      \+               184                   20488.5      4.93     Hypothetical protein
  ORF13      7,839       8,414      \+               191                   21491.9      6.78     Hypothetical protein
  ORF14      8,442       10,265     --               607                   65194.4      4.79     Putative tail tip protein
  ORF15      10,346      10,630     \+               94                    10251.1      7.28     Hypothetical protein
  ORF16      10,582      11,253     --               223                   23211.6      8.18     Hypothetical protein
  ORF17      11,256      11558      --               100                   10216.6      8.5      Hypothetical protein
  ORF18      11,596      15,015     --               1,139                 125892.9     5.11     Putative tail fiber protein
  ORF19      15,012      15629      --               205                   21245.4      8.71     Putative tail assembly protein I
  ORF20      15,620      16,360     --               246                   27577.5      4.95     Tail assembly protein
  ORF21      16,363      17,151     --               262                   28806.3      4.88     Putative minor tail protein L
  ORF22      17,148      17,747     --               199                   21696.3      6.52     Putative minor tail protein
  ORF23      17,784      20,426     --               880                   93307.2      9.93     Putative tail length tape-measure protein 1
  ORF24      20,426      20,518     --               30                    3341.4       10.5     Hypothetical protein
  ORF25      20,490      20,681     --               63                    6931.5       8.51     Hypothetical protein
  ORF26      20,821      21,051     --               76                    8543.3       5.77     Hypothetical protein
  ORF27      21,135      21,497     --               120                   13958.5      4.78     Hypothetical protein
  ORF28      21,567      22,292     --               241                   25755.3      5.82     Putative major tail protein
  ORF29      22,354      22,776     --               140                   15087.1      4.73     Hypothetical protein
  ORF30      22,776      23,369     --               197                   21918        11.19    Putative tail protein
  ORF31      23,371      23,730     --               119                   13053.8      9.59     Putative structural protein
  ORF32      23,711      23,827     --               38                    3990.7       3.76     Hypothetical protein
  ORF33      23,829      24,359     --               176                   18924.7      3.89     Hypothetical protein
  ORF34      24,388      25,488     --               366                   38395.4      7.66     Major head protein
  ORF35      25,586      26,287     --               233                   25384.1      5.51     Hypothetical protein
  ORF36      26,388      26,756     \+               122                   13128.6      5.65     Hypothetical protein
  ORF37      26,796      27,560     \+               254                   28937.1      8.29     Hypothetical protein
  ORF38      27,574      27,732     --               52                    5739.7       4.33     Hypothetical protein
  ORF39      27,686      28,015     --               109                   11931.4      9.88     Hypothetical protein
  ORF40      28,008      29,111     --               367                   40988.6      9.94     Head morphogenesis protein
  ORF41      29,095      30,615     --               506                   55192.3      4.51     Phage structural protein
  ORF42      30,627      32,012     --               461                   52196.7      7.52     Terminase large subunit
  ORF43      32,012      32,584     --               190                   21084        8.05     Putative terminase small subunit
  ORF44      32,694      33,836     --               380                   42737.4      7.35     Putative phosphoesterase
  ORF45      33,857      34,057     \+               66                    7221.1       8.22     Hypothetical protein
  ORF46      34,074      34,241     --               55                    5603.2       4.48     Hypothetical protein
  ORF47      34,258      34,749     --               163                   18156.3      9.41     Lysozyme
  ORF48      34,736      34,981     --               81                    8870         8.51     Putative holin-like class I protein
  ORF49      34,978      35,268     --               96                    10183.1      8.23     Putative holin-like class II protein
  ORF50      35,323      35,622     --               99                    11796        9.72     Hypothetical protein
  ORF51      35,687      35,833     --               48                    5626.5       11.71    Hypothetical protein
  ORF52      35,830      36,363     --               177                   20721.2      10.59    Hypothetical protein
  ORF53      36,360      36,494     --               44                    5107.7       3.43     Hypothetical protein
  ORF54      36,485      36,670     --               61                    7413.4       11.48    Hypothetical protein
  ORF55      36,770      37,075     --               101                   11091.8      10.31    Hypothetical protein
  ORF56      37,072      37,206     --               44                    5206.2       8.24     Hypothetical protein
  ORF57      37,297      37,554     --               85                    9233.9       11.49    Hypothetical protein
  ORF58      37,609      39,861     --               750                   82443.1      6.15     Hypothetical protein
  ORF59      39,872      40,201     --               109                   12545.1      8.47     DNA recombination nuclease inhibitor gamma
  ORF60      40,424      41,032     \+               202                   23053.6      4.52     Hypothetical protein
  ORF61      41,081      41,332     \+               83                    9953.6       9.91     Hypothetical protein
  ORF62      41,333      41,521     \+               62                    7168         8.22     Hypothetical protein
  ORF63      41,521      42,951     \+               476                   52319.8      8.73     Hypothetical protein
  ORF64      42,944      43,186     \+               80                    9323.4       6.49     Hypothetical protein
  ORF65      43,277      44,059     \+               260                   29909.5      4.55     Hypothetical protein

![Map of the genome organization of bacteriophage vB_EcoS-B2. The predicted ORFs are indicated as different colors in first circle. The outward showed the forward transcription genes and the inward showed the reversed transcription genes. Different colors identify ORFs with predicted molecular function. Hypothetical proteins marked by black. The second circle shows the G/C content. Red outward indicated that the G/C content of this region is higher than the average G/C content of the whole genome, and blue inward indicated G/C content of this region less than the average. The third circle shows the GC skew. Particle proteins identified by Mass spectrometry were pointed by black arrows.](fmicb-09-00793-g0003){#F3}

Structural proteins of vB_EcoS-B2
---------------------------------

In order to analyze the structural proteins of vB_EcoS-B2, purified phage particles were denatured by boiling with sample buffer, and then separated by SDS-PAGE. At least seven distinct protein bands, with molecular weights ranging from 28.8 to 125.9 kDa, were visualized in the SDS-PAGE gel (Figure [4](#F4){ref-type="fig"}). Five bands were identified as phage structural proteins (Major head protein, Putative minor tail protein L, Phage structural protein, Putative tail tip protein, and Putative tail fiber protein), and two bands were identified as hypothetical proteins (Figure [4](#F4){ref-type="fig"}). To determine every structural protein, phage particle proteins were identified by mass spectrometry, and results were listed in Table [3](#T3){ref-type="table"}. Twenty-one proteins were identified in mass spectrometry, including proteins corresponding to all seven distinct bands on SDS-PAGE gel (Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"}). Twelve out of 13 known structural proteins were identified by mass spectrometry, and some hypothetical proteins (ORF16, ORF29, ORF32, ORF33, ORF35, ORF46, ORF63) were also identified, which may be some unknown structural proteins. Interestingly, DNA polymerase I and putative phosphoesterase were determined in our phage particles. DNA polymerase I could fill DNA gaps during DNA repair, recombination, and replication (Andraos et al., [@B3]). DNA polymerase I and putative phosphoesterase may play important roles in the phage early infection processes, which will be our interests in our further studies.

![vB_EcoS-B2 virion structural proteins. The purified vB_EcoS-B2 particles were denatured and separated by SDS-PAGE and stained with silver. The positions of seven bands corresponding to different structure proteins are indicated on the right. Molecular mass markers are shown on the left.](fmicb-09-00793-g0004){#F4}

###### 

Mass spectrometry data for vB_EcoS-B2.

  **ORFs**   **Predicted molecular function**              **Peptides**   **Unique peptides**   **Unique sequence coverage \[%\]**   **MW(da)**
  ---------- --------------------------------------------- -------------- --------------------- ------------------------------------ ------------
  ORF23      Putative tail length tape-measure protein 1   70             70                    77.4                                 93307.2
  ORF18      Putative tail fiber protein                   52             52                    59.2                                 125892.9
  ORF34      Major head protein                            40             40                    86.1                                 38395.4
  ORF14      Putative tail tip protein                     36             36                    56.7                                 65194.4
  ORF41      Phage structural protein                      31             31                    72.7                                 55192.3
  ORF28      Putative major tail protein                   25             25                    83.9                                 25755.3
  ORF40      Head morphogenesis protein                    24             24                    61                                   40988.6
  ORF21      Putative minor tail protein L                 18             18                    63.4                                 28806.3
  ORF44      Putative phosphoesterase                      13             13                    36.6                                 42737.4
  ORF35      Hypothetical protein                          13             13                    56.2                                 25384.1
  ORF22      Putative minor tail protein                   11             11                    51.5                                 21696.3
  ORF30      Putative tail protein                         9              9                     43.1                                 21918
  ORF33      Hypothetical protein                          7              7                     54.2                                 18924.7
  ORF31      Putative structural protein                   7              7                     58.7                                 13053.8
  ORF46      Hypothetical protein                          5              5                     94.5                                 5603.2
  ORF16      Hypothetical protein                          5              5                     38.6                                 23211.6
  ORF63      Hypothetical protein                          4              4                     15.4                                 52319.8
  ORF29      Hypothetical protein                          3              3                     41.1                                 15087.1
  ORF1       DNA polymerase I                              3              3                     8.5                                  86167.7
  ORF32      Hypothetical protein                          2              2                     22.3                                 3990.7
  ORF19      Putative tail assembly protein I              2              2                     21                                   21245.4

*Particles proteins detected by MS are listed with their predicted functions and molecular mass. Molecular mass was calculated from the amino acid sequence of each gene. Number of identified peptides and unique peptides in each protein and the corresponding unique peptide sequence coverage are also indicated*.

Comparative genome analysis
---------------------------

Based on the result of BLAST analyses, the genome sequence of vB_EcoS-B2 displays significant similarity (coverage 87--95%, identity 90--94%) to 14 phages isolated from different regions around the world, suggesting that the complex evolutionary relationships exist among these phages. The corresponding genome sequences of these phages were aligned, concatenated, and a phylogenetic tree was built using the maximum likelihood method (Figure [5](#F5){ref-type="fig"}). Phylogenetic tree of these phages has two main branches. Phylogenetic tree analysis showed that vB_EcoS-B2 is a novel bacteriophage that is closely related to phages JL1, YD-2008.s, Sloth, Envy, slur05, and lust, and relatively distant to phages SSL-2009a, HK578, EK99P-1, Sodalis phage SO-1, Shigella phage EP23, slur06, Gluttony, and Pride (Figure [5](#F5){ref-type="fig"}). The results of the comparative genomic analyses extend our understanding of the evolution and relationship between vB_EcoS-B2 and its bacteriophage relatives.

![Phylogenetic tree based on whole genome sequence comparisons of selected phages. Whole genome sequence comparison was compared using the ClustalW program, and the phylogenetic tree was generated using the neighbor-joining method with 1,000 bootstrap replicates. vB_EcoS-B2 in brief is"B2"in this phylogenetic trees.](fmicb-09-00793-g0005){#F5}

Most of the proteins from vB_EcoS-B2 and 14 relative phages are homology with each other. But some blank regions could be observed though genome comparison of these phages (Figure [6](#F6){ref-type="fig"}). The phage tail tip protein encoded by ORF14 shows a greater divergence between these phages (43--99% coverage and 68--85% identity) (Figure [6](#F6){ref-type="fig"}). The ORF14 is relatively similar to tail fiber protein of phage Envy (99% coverage and 70% identity). The tail proteins are thought to be involved in host recognition, and confer the phage host range specificity (Hashemolhosseini et al., [@B21]). The small differences in tail fiber proteins are often associated with significant differences in host ranges and other biological properties (Yosef et al., [@B46]). This putative tail tip protein of vB_EcoS-B2 is relatively different from tail tip/fiber proteins of other phages, which may make the host range of phage vB_EcoS-B2 different from other relative phages.

![Schematic genomic alignment of the phage vB_EcoS-B2 with other 14 homologous phages. Homologous ORFs or genes are present in blue, and the percentages of amino acid identities are shown with different colors.](fmicb-09-00793-g0006){#F6}

Multiple alignment of the vB_EcoS-B2 and 14 relative phages showed that most of regions are highly homologous at protein levels, but they exhibit different gene arrangement with each other (Figure [6](#F6){ref-type="fig"}). For example, DNA polymerase I and DNA helicase regions of vB_EcoS-B2 were reversely matched with phage SSL-2009a. The tail protein region of phage vB_EcoS-B2 was forwardly matched with the same regions of Enterobacteria phage SSL-2009a. But head morphogenesis protein, terminase large subunit, and lysozyme regions, were back to reversely matched with phage SSL-2009a (Figure [6](#F6){ref-type="fig"}). Pan et al. found that the gene arrangement and genome structure of phage JL1 are different from those of the other four phages, such as SSL-2009a (Pan et al., [@B32]). EP23 and SSL-2009a had high similarities in amino acid sequences (95.5% on average). But their gene orders were not conserved with each other (Chang and Kim, [@B12]). A lot of gene inversions and rearrangement were observed between these phages, such as YD-2008s and SSL-2009a, JL1 and HK578, EK99P-1 and sloth, Envy and Gluttony, Pride and lust, SO-1and slur05 (Figure [6](#F6){ref-type="fig"}). Gene recombination seems to have been occurred in high frequency in these phages (Figure [6](#F6){ref-type="fig"}). Our results convinced that topological rearrangement of genomes has lower barriers than changes of amino acid sequences during evolution of phage vB_EcoS-B2 with its phage relatives (Li et al., [@B29]; Chang and Kim, [@B12]; Pan et al., [@B32]). Gene order has major effects on growth rate for T7 phage even when genome entry is normal, suggesting that the consequence of altered gene order probably extends to fitness measures that are not tied to a short generation time (Cecchini et al., [@B11]). vB_EcoS-B2 and its relatives may be co-evoluted with their host through rearrangement of their genes under different selection pressures. Tailed bacteriophages constitute the most abundant and diverse group of dsDNA viruses, in which evolution is very complicated (Iranzo et al., [@B24]). Several results illustrated that phages may undergo genetic exchange by horizontal gene transfer from a large shared pool, and that horizontal gene transfer between phages is a component of evolution (Håggard-Ljungquist et al., [@B19]; Hendrix et al., [@B22]; Casjens, [@B9]; Dekel-Bird et al., [@B15]; Chen et al., [@B13]). In our study, both horizontal exchange and vertical gene order rearrangement may affect the organization of bacteriophage genomes and blur phylogenetic reconstructions in vB_EcoS-B2 and its relative phages.

In conclusion, we have isolated and characterized a new lytic phage vB_EcoS-B2 which belongs to family *Siphoviridae*, with lytic activity against several MDR *E. coli* isolates. vB_EcoS-B2, like JL1 and EP23, can be assigned into virulent phages because of the presence of lysis genes such as lysozyme, putative holin-like class I protein and putative holin-like class II protein, and no similarities to lysogenic genes coding integrase, repressor, and anti-repressor proteins. The genome sequence analysis of vB_EcoS-B2 provided no evidence of genes related to potential virulence factors or antibiotic resistance genes. In addition, the identification of the 21 structural proteins confirmed that the vB_EcoS-B2 is a new virulent bacteriophage of *E. coli*. It also demonstrated a high degree of identity of vB_EcoS-B2 with ORFs from some other phages. Genome and proteome analysis confirmed the lytic nature of the vB_EcoS-B2. Comparative genome analysis sheds light on the mechanisms of evolutionary changes of these phage genomes. Our results indicate that gene arrangement and genome structure of phage vB_EcoS-B2 is different from that of its phage relatives. The vB_EcoS-B2 genome encodes several putative proteins, including enzymes with antimicrobial activity for the biocontrol of pathogenic bacteria or involved in the phage infection process. The phage genome sequence data also provide useful basic information for further research on the interaction between phages and their hosts.
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